Evaluation of the VersaTREK System Compared to the Bactec MGIT 960 System for First-Line Drug Susceptibility Testing of Mycobacterium tuberculosis
| Autor: | Pere Coll, Margarita Salvadó, Nuria Martín-Casabona, M. Torra, Griselda Tudó, Dionisia Fontanals, Fernando Alcaide, Mateu Espasa, Eva Vicente, Julian Gonzalez-Martin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Tuberculosis biology business.industry First line Isoniazid Antitubercular Agents Mycobacteriology and Aerobic Actinomycetes Microbial Sensitivity Tests Mycobacterium tuberculosis Drug susceptibility Pyrazinamide bacterial infections and mycoses medicine.disease biology.organism_classification Streptomycin Internal medicine Humans Medicine business Ethambutol medicine.drug |
| Zdroj: | JOURNAL OF CLINICAL MICROBIOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 1098-660X 0095-1137 |
| Popis: | The aim of this study was to evaluate the reliability of the VersaTREK system for Mycobacterium tuberculosis drug susceptibility testing compared with results obtained with the Bactec MGIT 960 system. A total of 67 strains were evaluated. Overall agreement was at 98.5%. Kappa indexes were 1.0 for isoniazid, rifampin, and ethambutol, 0.937 for pyrazinamide, and 0.907 for streptomycin. The VersaTREK system is validated for M. tuberculosis drug susceptibility testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|